NASDAQ: INBSIntelligent Bio Solutions Inc Stock
$2.35-0.07 (-2.89%)
Updated Jun 10, 2026
INBS Price
$2.35
Fair Value Price
N/A
Market Cap
$5.62M
52 Week Low
$2.24
52 Week High
$24.90
P/E
-0.19x
P/B
0.63x
P/S
1.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.73M
Earnings
-$11.61M
Gross Margin
56.3%
Operating Margin
-244.02%
Profit Margin
-245.6%
Debt to Equity
0.68
Operating Cash Flow
-$11M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INBS Overview
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INBS's potential to beat the market
- INBS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
INBS
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.05 | A | |
| $37.18 | A | |
| $25.97 | A |
Be the first to know about important INBS news, forecast changes, insider trades & much more!
INBS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INBS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INBS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INBS is good value based on its book value relative to its share price (0.63x), compared to the US Medical Devices industry average (3.01x)
P/B vs Industry Valuation
INBS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INBS due diligence checks available for Premium users.
Valuation
INBS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
22.22x
Market
14.77x
INBS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
3.01x
INBS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INBS's financial health
Profit margin
Revenue
$1.2M
Net Income
-$2.9M
Profit Margin
-233.4%
INBS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INBS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.9M
Liabilities
$6.1M
Debt to equity
0.68
INBS's short-term assets ($9.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INBS's short-term assets ($9.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INBS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INBS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
$12.9k
Financing
$10.4M
INBS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INBS vs Medical Device Stocks
Intelligent Bio Solutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.